1. Oscar Health for Medicare Advantage

2. A tech-driven Humana

• Medicare Advantage PPO Health Plans: Health insurance plans structured as Preferred Provider Organizations for Medicare-eligible individuals.
• Medicare Advantage HMO Health Plans: Health insurance plans structured as Health Maintenance Organizations for Medicare-eligible individuals.
• Clover Assistant Platform: A proprietary software platform utilized to deliver and manage the company's Medicare Advantage health plans for members.

Clover Health Investments (CLOV) primarily sells its services, which are Medicare Advantage health plans, directly to individuals rather than to other companies.

The company serves the following categories of customers:

• Medicare-eligible individuals: These are consumers who qualify for Medicare benefits, typically those aged 65 or older, or younger individuals with certain disabilities. They are the fundamental customer base for all of Clover Health's offerings.
• Seniors and the elderly: Representing the core demographic, this category encompasses the vast majority of Clover Health's direct members who are aged 65 and above and are seeking health coverage.
• Individuals seeking comprehensive managed care plans (HMO/PPO): These customers specifically choose Medicare Advantage plans for their integrated benefits, care coordination, and potentially lower out-of-pocket costs compared to Original Medicare. They opt for Clover Health's Preferred Provider Organization (PPO) or Health Maintenance Organization (HMO) plan offerings.

• Cigna Group (CI) (via its subsidiary Express Scripts)

Andrew Toy, Chief Executive Officer

Andrew Toy was appointed CEO of Clover Health in January 2023. Prior to this, he served as President and Chief Technology Officer for the company. Before joining Clover Health in 2018, Toy was at Google, where he worked on the Google Cloud team and led Android for Work. He co-founded Divide, a company focused on splitting work and personal data on mobile devices, which Google acquired in 2014 for $120 million. He holds a B.S. and M.S. in Computer Science from Stanford University.

Peter Kuipers, Chief Financial Officer

Peter Kuipers was appointed Chief Financial Officer of Clover Health, effective April 22, 2024. He brings over 25 years of technology leadership experience to the role. Prior to Clover Health, Mr. Kuipers served as Executive Vice President and CFO at Omnicell, Inc., a healthcare technology company, contributing to its revenue growth from $485 million to $1.3 billion. He also held CFO positions at Quantcast and The Weather Company. His extensive background includes divisional CFO and executive FP&A leadership roles at Yahoo!, Altera Corporation (acquired by Intel), General Electric Company, and Akzo Nobel.

Vivek Garipalli, Co-founder and Executive Chairperson

Vivek Garipalli co-founded Clover Health in 2014 and served as its Chief Executive Officer from July 2014 to December 2022. He became Executive Chairperson of the Board in January 2023. Before Clover Health, Garipalli co-founded CarePoint Health, a fully integrated healthcare system in New Jersey, in 2008. He also co-founded Ensemble Health, a healthcare services revenue cycle company, and was a founding investor and board member of Flatiron Health, which was sold to Roche in 2018. He began his career in finance at Credit Suisse First Boston, J.P. Morgan Partners, and Blackstone Group.

Conrad Wai, Chief Executive Officer of Counterpart Health

Conrad Wai is the Chief Executive Officer of Counterpart Health, a wholly-owned subsidiary of Clover Health that houses its flagship technology solution, since September 2024. He previously served as Clover Health's Chief Technology Officer from February 2022 to September 2024. Before joining Clover, Wai was Senior Vice President of Product for Hinge Health and held product leadership positions at Yahoo! Inc. and Google. He holds B.S. and M.S. degrees in Computer Science from Stanford University.

Dr. Kumar Dharmarajan, Chief Scientific Officer

Dr. Kumar Dharmarajan is the Chief Scientific Officer at Clover Health, where he leads clinical programs and R&D initiatives for medically complex members. He is a cardiologist and geriatrician. Prior to Clover Health, Dr. Dharmarajan was a faculty member at Yale, focusing on improving hospital and post-acute care for older patients through research for the Centers for Medicare and Medicaid Services. He is also a co-founder and Chief Medical Officer of WorldClass Health since March 2024. He earned his A.B. at Harvard and M.D. and MBA at Columbia.

The key risks for Clover Health Investments (CLOV) are primarily centered around the highly regulated nature of the Medicare Advantage sector, ongoing profitability challenges due to elevated medical costs, and intense market competition coupled with the need for successful technological scaling.

1. Regulatory Dependence and Changes in Medicare Advantage Policies: Clover Health operates within a heavily regulated healthcare environment and is highly reliant on Medicare Advantage (MA) premiums and government policies. Changes in Medicare regulations, reimbursement rates, healthcare policies, and risk adjustment mechanisms can have a material adverse effect on the company's operations and financial performance. For instance, potential legislative changes, such as automatic Medicare spending reductions or unfavorable rate notices, could lead to lower risk scores and reimbursements, affecting Clover Health's revenue and requiring it to absorb higher medical costs or reduce benefits.
2. Financial Performance, Profitability Concerns, and Elevated Medical Costs: Clover Health has a history of consistent net losses and faces significant challenges in achieving and sustaining profitability. The company has reported ongoing net losses for several years, raising concerns about its long-term financial viability. A key driver of these struggles is elevated medical costs, reflected in an increased Insurance Benefit Expense Ratio (BER), which puts pressure on insurance margins. New member acquisitions, in particular, tend to incur higher initial medical costs, impacting short-term profitability.
3. Competitive Landscape and Execution Risks in Scaling Technology: The Medicare Advantage market is highly competitive, with numerous established insurers and new entrants vying for market share. Rivals often develop their own technologies or partner with third-party providers, requiring Clover Health to continuously innovate and differentiate its offerings. While the Clover Assistant software platform is a core strength, there are inherent execution risks in successfully scaling this technology, ensuring deep physician adoption, and effectively translating clinical engagement into sustained economic benefits. Failure to do so could hamper its competitive edge and profitability.

The increasing emphasis and expansion of **provider-led value-based care models**, such as Accountable Care Organizations (ACOs) and the newer ACO REACH program, represent a clear emerging threat. These models enable healthcare providers to assume direct financial risk and manage the care of Medicare beneficiaries directly, potentially disintermediating traditional Medicare Advantage insurers like Clover Health. By empowering providers to directly contract with Medicare and manage populations with integrated technology and care delivery, these models could diminish the need for third-party MA plans and attract beneficiaries away from them, thereby challenging Clover's core business model as an intermediary.

The addressable market for Clover Health Investments (CLOV), primarily a Medicare Advantage insurer, is the Medicare Advantage market in the United States.

As of February 1, 2026, over 35 million people are enrolled in Medicare Advantage plans in the United States. This represents 51% of the total 69 million Medicare-eligible individuals. In 2025, enrollment reached 34.1 million beneficiaries, accounting for 54% of all Medicare-eligible individuals. The global Medicare Advantage market size, which includes the U.S. market where Clover Health operates, was estimated at approximately USD 445.97 billion in 2025 and is projected to grow to about USD 1.06 trillion by 2034. In 2024, the Medicare program paid Medicare Advantage plans an estimated $494 billion to cover Part A and Part B services for enrollees.

• Medicare Advantage Membership Growth: Clover Health projects a substantial increase in its Medicare Advantage (MA) membership. For 2026, the company anticipates MA membership to reach between 154,000 and 158,000, representing approximately 46% year-over-year growth at the midpoint. This growth in its core insurance business is expected to be a primary driver of revenue. The company's 2025 Medicare Advantage enrollment rose 38% year over year, ending the year with approximately 114,000 members. Analysts project future revenues of $1.6 billion in 2025 and $1.8 billion in 2026, indicating a strong growth outlook. The company is guiding for total revenues between $2.81 billion and $2.92 billion for 2026.
• Increased Adoption and Effectiveness of Clover Assistant: The proprietary software platform, Clover Assistant, is central to Clover Health's strategy. This AI-powered tool provides real-time, personalized recommendations to physicians, aiming to improve clinical decision-making, enhance patient outcomes, and ultimately reduce healthcare costs. Deeper engagement with Clover Assistant and expanded adoption by primary care physicians (PCPs) are expected to drive better health outcomes and improve the medical cost ratio, supporting sustainable growth and profitability.
• Expansion of Market Reach and Technology Platform (including Counterpart Health): Clover Health is focused on expanding its market reach, including exploring opportunities for geographic expansion and diversifying its product offerings. A significant aspect of this expansion is the strategic growth of its technology platform through Counterpart Health, which extends the Clover Assistant beyond Clover Health's owned Medicare Advantage plans to outside providers. This allows for monetization of its technology and serves as a parallel long-term growth engine.
• Improved Member Retention and Higher CMS Star Ratings: High member retention, reported at over 95%, contributes to sustained revenue as older cohorts mature on the platform, and profitability improves with tenure. Furthermore, Clover Health's flagship PPO plan, covering over 95% of its members, achieved a 4-Star rating from CMS. This improved rating qualifies the company for higher quality bonus payments and stronger plan-level economics, which should further support membership growth and revenue expansion. The company expects 2026 to be a 4-star payment year, benefiting 97% of members in its PPO plan.

Share Repurchases

• Clover Health authorized a share repurchase program of up to $20 million in May 2024, valid for two years.
• As of September 2025, Clover Health Investments' 6-Month Share Buyback Ratio was -1.51%, which may indicate potential share issuance rather than significant buybacks or no buybacks during that period.

Share Issuance

• In November 2021, Clover Health completed an underwritten public offering of its Class A Common Stock, generating approximately $300 million in gross proceeds.
• In March 2026, Clover Health registered an additional 14,618,641 shares of Class A common stock under its 2020 Equity Incentive Plan and 4,266,694 shares under its 2020 Employee Stock Purchase Plan, due to automatic increases.
• Cash flows from financing activities for the year ended December 31, 2025, included $718 thousand from the issuance of common stock (net of early exercise liability) and $1,096 thousand from the issuance of common stock under an employee stock purchase plan (net of stock issuance costs).

Outbound Investments

• Clover Health is extending its Clover Assistant technology to external partners through its subsidiary, Counterpart Health, as an asset-light, technology platform strategy and a SaaS and tech-enabled services offering.

Capital Expenditures

• Capital expenditures in the most recent reported quarter totaled approximately -$0.597 million USD.
• The company's strategy involves continued investment in its Clover Assistant software, clinical programs, and geographic expansion.